Edition:
India

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

474.10DKK
22 Jun 2018
Change (% chg)

kr.4.10 (+0.87%)
Prev Close
kr.470.00
Open
kr.470.00
Day's High
kr.475.30
Day's Low
kr.467.00
Volume
147,992
Avg. Vol
362,420
52-wk High
kr.477.70
52-wk Low
kr.280.80

Latest Key Developments (Source: Significant Developments)

Lundbeck Reaches Voluntary Agreement In Principle With U.S. DOJ
Thursday, 7 Jun 2018 

June 6 (Reuters) - H Lundbeck A/S ::REACHES VOLUNTARY AGREEMENT IN PRINCIPLE WITH U.S. DEPARTMENT OF JUSTICE.AS PART OF AGREEMENT, LUNDBECK LLC WILL PAY DOJ $52.6 MILLION (APPROXIMATELY DKK 336 MILLION).AGREEMENT WILL HAVE NO INFLUENCE ON LUNDBECK'S GUIDANCE FOR 2018, WHICH WAS PROVIDED ON 7 FEBRUARY 2018.  Full Article

Otsuka Holdings unit and Lundbeck to start third phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with Alzheimer's disease
Thursday, 24 May 2018 

May 24 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says co's unit Otsuka Pharmaceutical Co Ltd and Lundbeck announce that the two companies' third clinical phase 3 study ofbrexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.  Full Article

Lundbeck Q1 EBIT Above Expectations At DKK 1.66 Billion
Tuesday, 8 May 2018 

May 8 (Reuters) - H LUNDBECK A/S ::FINANCIAL GUIDANCE FOR 2018 IS UNCHANGED.Q1 REVENUE DKK 4.59 BILLION (REUTERS POLL DKK 4.35 BILLION).Q1 EBIT REACHED DKK 1,656 MILLION COMPARED TO DKK 1,011 MILLION IN Q1 OF 2017.FINANCIAL GUIDANCE FOR 2018 IS UNCHANGED.Q1 EBIT DKK 1.66 BILLION (REUTERS POLL DKK 1.21 BILLION).AS A CONSEQUENCE OF THE U.S. TAX REFORM, LUNDBECK EXPECTS THE REPORTED TAX RATE TO BE 26-28% COMPARED TO 38.7% IN 2017.  Full Article

H Lundbeck says FDA updates Trintellix label to include data showing improvement in processing speed
Thursday, 3 May 2018 

May 2 (Reuters) - H Lundbeck A/S ::REG-FDA UPDATES TRINTELLIX® (VORTIOXETINE) LABEL TO INCLUDE DATA SHOWING IMPROVEMENT IN PROCESSING SPEED, AN IMPORTANT ASPECT OF COGNITIVE FUNCTION IN ACUTE MAJOR DEPRESSIVE DISORDER (MDD).U.S. FDA APPROVED A SUPPLEMENTAL NEW DRUG APPLICATION FOR TRINTELLIX (VORTIOXETINE).FOCUS AND CONNECT STUDIES SHOW TRINTELLIX HAS A POSITIVE EFFECT ON PROCESSING SPEED.  Full Article

Lundbeck: Brintellix Approved In China
Monday, 4 Dec 2017 

Dec 4 (Reuters) - H Lundbeck A/S ::’S BRINTELLIX APPROVED IN CHINA.LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018..  Full Article

Lundbeck Q3 EBIT above expectations at DKK 1.42‍​ bln
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - H LUNDBECK AS ::LUNDBECK INCREASED OPERATING PROFIT (EBIT) WITH 126% AND EPS BY 182% IN THE FIRST NINE MONTHS OF 2017 <<>>.‍NOW EXPECTS REVENUE TO REACH DKK 16.9-17.4 BILLION AND EBIT TO REACH DKK 4.3-4.6 BILLION FOR 2017​.‍REVENUE REACHED DKK 12,842 MILLION IN FIRST NINE MONTHS OF 2017​.‍PREVIOUSLY EXPECTED REVENUE OF DKK 16.7-17.5 BILLION AND EBIT OF DKK 4.1-4.5 BILLION​.Q3 REVENUE DKK 4.35‍​ BILLION (REUTERS POLL DKK 4.38 BILLION).Q3 EBIT DKK 1.42‍​ BILLION (REUTERS POLL DKK 1.19 BILLION).  Full Article

Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018.  Full Article

Lundbeck chairman says interim CEO will not become permanent CEO
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - LUNDBECK CHAIRMAN SAYS:INTERIM CEO GOTZSCHE WILL NOT BECOME PERMANENT CEO FOR LUNDBECK.CERTAIN NEXT CEO WILL BE EXTERNAL CANDIDATE.  Full Article

Lundbeck says Anders Gotzsche to be interim CEO from Nov 1
Tuesday, 31 Oct 2017 

Oct 30 (Reuters) - Lundbeck - :CHANGES TO LUNDBECK'S EXECUTIVE MANAGEMENT .‍BOARD DECIDED THAT AS OF NOV 1 ANDERS GÖTZSCHE WILL TAKE OVER OPERATIONAL MANAGEMENT OF CO AS INTERIM CEO UNTIL NEW CEO IS IN PLACE​.  Full Article

Otsuka and Lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with bipolar I disorder
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:unit Otsuka Pharmaceutical Co., Ltd. and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder.  Full Article

UPDATE 1-Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

BOSTON, June 6 Danish drugmaker Lundbeck said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.